Samuele Nardoni

Dr. Samuele Nardoni


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
Elena BertelliElena Bertelli
Elena Bertelli
MVMichele Vizzi
Michele Vizzi
Chiara MarziChiara Marzi
Chiara Marzi
SPSandro Pastacaldi
Sandro Pastacaldi
ACAlberto Cinelli
Alberto Cinelli
VMVittorio Miele
Vittorio Miele
Background: Biparametric MRI (bpMRI) has an important role in the diagnosis of prostate cancer (PCa), by reducing the cost and duration of the procedure and adverse reactions. We assess the additional benefit of the ADC map in detecting prostate cancer (PCa). Additionally, we examine whether the ADC value correlates with the presence of clinically significant tumors (csPCa). Methods: 104 peripheral lesions classified as PI-RADS v2.1 score 3 or 3+1 at the mpMRI underwent transperineal MRI/US fusion-guided targeted biopsy. Results: The lesions were classified as PI-RADS 3 or 3+1; at histopathology, 30 were adenocarcinomas, 21 of which were classified as csPCa. The ADC threshold that maximized the Youden index in order to predict the presence of a tumor was 1103 (95% CI (990, 1243)), with a sensitivity of 0.8 and a specificity of 0.59; both values were greater than those found using the contrast medium, which were 0.5 and 0.54, respectively. Similar results were also found with csPCa, where the optimal ADC threshold was 1096 (95% CI (988, 1096)), with a sensitivity of 0.86 and specificity of 0.59, compared to 0.49 and 0.59 observed in the mpMRI. Conclusions: Our study confirms the possible use of a quantitative parameter (ADC value) in the risk stratification of csPCa, by reducing the number of biopsies and, therefore, the number of unwarranted diagnoses of PCa and the risk of overtreatment.

20 December 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
GMGiulia Misasi
Giulia Misasi
CCClaudia Lucia Catucci
Claudia Lucia Catucci
SNSamuele Nardoni
Samuele Nardoni
BTBeatrice Turchi
Beatrice Turchi
EPElena Pisacreta
Elena Pisacreta
VMVincenzo Li Marzi
Vincenzo Li Marzi
Introduction an objective: Urinary tract infections (UTIs) are a significant health concern with high costs and poor quality of life (QoL) impact. Managing recurrent UTIs (rUTI) in women requires effective treatments that relieve symptoms and reduce recurrence, while also sparing antibiotics due to rising resistance. This study evaluates the efficacy of a nutritional supplement in reducing UTI recurrences and improving QoL compared to antibiotic therapy. Materials and Methods: This is a multicentric case-control study involving female patients with rUTI. We compared the efficacy of a dietary supplement containing D-mannose 3gr, Palmitoylethanolamide 600 mg, N-acetylcysteine 600 mg, Lactobacillus rhamnosus 2x109, Hibiscus extract 400 mg- (1 sachet/day for 14 days per month for 6 months) against a low dose of Fosfomycin 3 g (one sachet every 10 days for 6 months). Patients were clinically (age, BMI, hormonal status, smoking, and sexual activity) and microbiologically (urine cultures with antibiograms) evaluated at baseline, after 3 months, and after 6 months of therapy. Validated questionnaires were administered to evaluate QoL (WHO-5) and satisfaction (PGI-I). UTI was defined by positive urine culture (bacterial load ≥105 CFU/ml) and patient reported lower urinary tract symptoms (LUTS). Results: A total of 55 patients were enrolled in the nutritional supplement group (NGroup) and 34 in the Fosfomycin group (FGroup). In the NGroup, the median age was 62.2±16.0, a median BMI of 27.2±3.8, 13 (23.6%) were smokers, 29 (52.7%) were sexually active, and 42 (76.4%) were postmenopausal. The mean number of UTI at baseline was 1.87±0.75, decreasing to 0.51±0.63 at 3 months (p<0.001) and 0.28±0.54 at 6 months (p<0.001). Adverse events (AEs) reported were 2 (3.6%) at 3 months and 1 (2.1%) at 6 months (mild gastrointestinal symptoms in all cases). Questionnaires indicated improvements in both QoL (WHO-5: 18.90±3.91 at 3 months and 20.2 ± 2.55 at 6 months; p<0.001) and satisfaction (PGI-I: 3.04±1.61 at 3 months and 2.43±1.26 at 6 months; p<0.001). In the FGroup, demographic data revealed a median age of 62.9±12.9, a median BMI of 23.5±3.0, 10 (29.4%) were smokers, 30 (88.2%) were postmenopausal and 18 (54.5%) were sexually active. The mean number of UTI at baseline was 2.68±0.81, also in this group we have an improvement at 3 months 0.87±0.54 (p<0.001), and at 6 months 0.67±0.80 (p<0.001). No AEs were reported. QoL improved (WHO-5: 17.80±1.40 to 21.4±2.19, p<0.001), but satisfaction declined (PGI-I increased from 2.20±0.41 to 4.05±0.69; p0.05). Lower satisfaction was observed in FGroup. Conclusions: Despite the limitations of this study, including a small patient population and the absence of a third placebo control group of patients, the oral preparation containing D-mannose, PEA, N-acetylcysteine, Lactobacillus rhamnosus and hibiscus extract may be a viable alternative to antibiotics for reducing rUTI in women.